13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001958125
Total reported value
$532.1M
$532.1M
33 檔
27.1%
During the Q4 2024 filing period, Catalio Capital Management, LP (CIK: 0001958125) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $532.1M across 33 reported positions.
During Q4 2024, Catalio Capital Management, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BDX | Becton Dickinson And Co | Stock-Healthcare | 7.38% | — | — | |
| 2 | ASND | Ascendis Pharma A/S | Stock-Other | 6.49% | -6.17% | EXIT | |
| 3 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 6.18% | -0.86% | — | |
| 4 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 6.04% | — | — | |
| 5 | 2655787D | Blueprint Medicines CORP | Stock-Other | 5.43% | — | — | |
| 6 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 5.40% | -0.30% | — | |
| 7 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 5.39% | -0.33% | — | |
| 8 | LIVN | LivaNova PLC | Stock-Other | 5.19% | — | — | |
| 9 | SEPN | Septerna Inc | Stock-Other | 5.13% | +1.89% | — | |
| 10 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.71% | -2.97% | EXIT | |
| 11 | NVST | Envista Holdings CORP | Stock-Healthcare | 4.30% | — | — | |
| 12 | VCYT | Veracyte Inc | Stock-Other | 4.25% | — | — | |
| 13 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 4.21% | — | — | |
| 14 | EXK | Exact Sciences CORP | Stock-Materials | 3.80% | — | — | |
| 15 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 3.64% | -9.22% | — | |
| 16 | QURE | uniQure N.V. | Stock-Other | 3.48% | -1.68% | EXIT | |
| 17 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.38% | +0.22% | — | |
| 18 | MASI* | Masimo CORP | Stock-Other | 3.16% | — | — | |
| 19 | IRON | Disc Medicine Inc | Stock-Other | 2.49% | +0.55% | — | |
| 20 | ADMA | Adma Biologics Inc | Stock-Healthcare | 1.92% | — | — | |
| 21 | NARIUSD | Inari Medical Inc | Stock-Other | 1.48% | — | — | |
| 22 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.42% | -3.92% | EXIT | |
| 23 | KROS | Keros Therapeutics Inc | Stock-Other | 1.41% | — | — | |
| 24 | TARA | Protara Therapeutic Inc | Stock-Other | 1.26% | -0.26% | — | |
| 25 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.53% | — | — | |
| 26 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.48% | — | — | |
| 27 | MGX | Metagenomi Therapeutics Inc | Stock-Other | 0.42% | -0.03% | — | |
| 28 | KPTIEUR | Karyopharm Therapeutics Inc | Stock-Other | 0.35% | — | — | |
| 29 | ZBIO | Zenas Biopharma Inc | Stock-Other | 0.34% | — | — | |
| 30 | HYPR | Hyperfine Inc | Stock-Other | 0.15% | +0.03% | — | |
| 31 | GUTS | Fractyl Health Inc | Stock-Other | 0.10% | +0.39% | — | |
| 32 | ATAI | AtaiBeckley Inc. | Stock-Other | 0.06% | — | — | |
| 33 | SNSEEUR | Sensei Biotherapeutics Inc | Stock-Other | 0.03% | — | — |
According to official SEC Form 13F filings, Catalio Capital Management, LP reported a total U.S. public equity portfolio value of $532.1M across 33 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BDX, ASND, BMY) accounted for 27.1% of total reported equity market value during Q4 2024.
During Q4 2024, Catalio Capital Management, LP's top holdings by market value included BDX (7.4%)、ASND (6.5%)、BMY (6.2%). The largest single position, BDX, represented 7.4% of total portfolio value.
In Q4 2024, Catalio Capital Management, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.